Last reviewed · How we verify
NCT02226874
Comparison of Two Dose Assessment Methods for Exposures to Nuclear Detonation Radiation
trial in Radiation Exposure in 30 participants. Completed in 31 May 2016.
31 May 2016
Quick facts
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 26 August 2014 |
| Primary completion | 31 May 2016 |
| Estimated completion | 31 May 2016 |
| Sites | 1 location across United States |
Conditions studied
- Radiation Exposure — all drugs for Radiation Exposure →
Sponsor
National Cancer Institute (NCI)
Who can join
Adults 80 to 90, male only, with Radiation Exposure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: \- The National Cancer Institute was funded to study how much radiation U.S. veterans who served in the 1950s were exposed to. Researchers want to estimate how much radiation these veterans received. They will use two methods and compare them. One is to interview the veterans and study their military records. The other is to take blood samples and look for certain types of changes in the blood cells. Being exposed to some kinds of radiation is known to cause changes in blood cells. The amount of changes to these cells tells scientists about how much radiation was received. Objectives: \- To better understand how to measure how much radiation a person has received. Eligibility: * Veterans who were exposed to radiation at a specific site in the Pacific in 1954 or other sites in the 1950s. * Veterans close in age to the first group, who have low levels of exposure to radiation. * Men about 25 years old with no exposure to radiation. Design: * Participants will have 1 visit, in their home. * All participants will have blood drawn. This will take 10 minutes. * The exposed veterans will be interviewed. They will answer questions about the nuclear events they experienced. This will take up to 40 minutes. * For the exposed veterans, researchers will look at their military records, if they can. They will estimate how much radiation the veteran received.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02226874
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Radiation Exposure
Currently open trials in the same condition.
- NCT06875583 — The Radiation ProtEction for Dose RedUction in the Cardiac CathEter Lab Study: The REDUCE Trial · NA · recruiting
- NCT07008716 — Omitting CTV for Primary Tumor in LS-SCLC · Phase 3 · recruiting
- NCT06384105 — Study of the Patient Radiation Dose During Five Endourological Procedures · NA · recruiting
- NCT06360627 — Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT · NA · recruiting
- NCT05203250 — Longitudinal Registry Including Patients Treated With Heavy Particles · recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02226874 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
- Last refreshed: 12 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02226874.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing